Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patien...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 2021-10, Vol.62 (10), p.1457-1460 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1460 |
|---|---|
| container_issue | 10 |
| container_start_page | 1457 |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 62 |
| creator | Suh, Minseok Im, Hyung-Jun Ryoo, Hyun Gee Kang, Keon Wook Jeong, Jae Min Prakash, Sneha Ballal, Sanjana Yadav, Madhav P Bal, Chandrasekhar Jeong, Chang Wook Kwak, Cheol Cheon, Gi Jeong |
| description | 68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging. |
| doi_str_mv | 10.2967/jnumed.120.258434 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8724887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2580728766</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1594-4e949d059ec473c0d79f0b7c9fbc88451d7c4b47ca05d46dab4ee6dc52216c5c3</originalsourceid><addsrcrecordid>eNpdUbtOKzEUtNBFEB4fQGfpNlAY7PWb4kpRBAEpQCSgXnlt5-IosZe1F0TLl7MQGqhmzpnR6DwAOCL4tNJCni1jv_bulFRDzRWjbAuMCKcccSHkHzDCRBDEOea7YC_nJcZYKKV2wC6lgkqu-Ai8X3njUEnoE-EkrVvThZwiTAso1NSg27uHMTze0Onj7ASa6DbK_P5mjAiBIcK5KcHHkuFrKE_wxheTy9CycN6lT-bhxETru3M4_mq13pbw4uF96d3bAdhemFX2h9-4Dx4vLx4mV2h2N72ejGeoJVwzxLxm2mGuvWWSWuykXuBGWr1orFKMEycta5i0BnPHhDMN8144y6uKCMst3Qf_Nrlt3wxns8PAnVnVbRfWpnurkwn1TyWGp_p_eqmVrJhScgg4_g7o0nPvc6nXIVu_WpnoU5_rimlGMWWaDNa_v6zL1HdxWK8ePoVlpaQQ9AOuxYcf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580728766</pqid></control><display><type>article</type><title>Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Suh, Minseok ; Im, Hyung-Jun ; Ryoo, Hyun Gee ; Kang, Keon Wook ; Jeong, Jae Min ; Prakash, Sneha ; Ballal, Sanjana ; Yadav, Madhav P ; Bal, Chandrasekhar ; Jeong, Chang Wook ; Kwak, Cheol ; Cheon, Gi Jeong</creator><creatorcontrib>Suh, Minseok ; Im, Hyung-Jun ; Ryoo, Hyun Gee ; Kang, Keon Wook ; Jeong, Jae Min ; Prakash, Sneha ; Ballal, Sanjana ; Yadav, Madhav P ; Bal, Chandrasekhar ; Jeong, Chang Wook ; Kwak, Cheol ; Cheon, Gi Jeong</creatorcontrib><description>68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.</description><identifier>ISSN: 0161-5505</identifier><identifier>ISSN: 1535-5667</identifier><identifier>EISSN: 1535-5667</identifier><identifier>DOI: 10.2967/jnumed.120.258434</identifier><identifier>PMID: 33637585</identifier><language>eng</language><publisher>New York: Society of Nuclear Medicine</publisher><subject>Antigens ; Brief Communications ; Computed tomography ; Lesions ; Medical imaging ; Metastases ; Metastasis ; Organs ; Positron emission ; Prostate cancer ; Tomography ; Urea</subject><ispartof>The Journal of nuclear medicine (1978), 2021-10, Vol.62 (10), p.1457-1460</ispartof><rights>Copyright Society of Nuclear Medicine Oct 1, 2021</rights><rights>2021 by the Society of Nuclear Medicine and Molecular Imaging.</rights><rights>2021 by the Society of Nuclear Medicine and Molecular Imaging. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Suh, Minseok</creatorcontrib><creatorcontrib>Im, Hyung-Jun</creatorcontrib><creatorcontrib>Ryoo, Hyun Gee</creatorcontrib><creatorcontrib>Kang, Keon Wook</creatorcontrib><creatorcontrib>Jeong, Jae Min</creatorcontrib><creatorcontrib>Prakash, Sneha</creatorcontrib><creatorcontrib>Ballal, Sanjana</creatorcontrib><creatorcontrib>Yadav, Madhav P</creatorcontrib><creatorcontrib>Bal, Chandrasekhar</creatorcontrib><creatorcontrib>Jeong, Chang Wook</creatorcontrib><creatorcontrib>Kwak, Cheol</creatorcontrib><creatorcontrib>Cheon, Gi Jeong</creatorcontrib><title>Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study</title><title>The Journal of nuclear medicine (1978)</title><description>68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.</description><subject>Antigens</subject><subject>Brief Communications</subject><subject>Computed tomography</subject><subject>Lesions</subject><subject>Medical imaging</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Organs</subject><subject>Positron emission</subject><subject>Prostate cancer</subject><subject>Tomography</subject><subject>Urea</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdUbtOKzEUtNBFEB4fQGfpNlAY7PWb4kpRBAEpQCSgXnlt5-IosZe1F0TLl7MQGqhmzpnR6DwAOCL4tNJCni1jv_bulFRDzRWjbAuMCKcccSHkHzDCRBDEOea7YC_nJcZYKKV2wC6lgkqu-Ai8X3njUEnoE-EkrVvThZwiTAso1NSg27uHMTze0Onj7ASa6DbK_P5mjAiBIcK5KcHHkuFrKE_wxheTy9CycN6lT-bhxETru3M4_mq13pbw4uF96d3bAdhemFX2h9-4Dx4vLx4mV2h2N72ejGeoJVwzxLxm2mGuvWWSWuykXuBGWr1orFKMEycta5i0BnPHhDMN8144y6uKCMst3Qf_Nrlt3wxns8PAnVnVbRfWpnurkwn1TyWGp_p_eqmVrJhScgg4_g7o0nPvc6nXIVu_WpnoU5_rimlGMWWaDNa_v6zL1HdxWK8ePoVlpaQQ9AOuxYcf</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Suh, Minseok</creator><creator>Im, Hyung-Jun</creator><creator>Ryoo, Hyun Gee</creator><creator>Kang, Keon Wook</creator><creator>Jeong, Jae Min</creator><creator>Prakash, Sneha</creator><creator>Ballal, Sanjana</creator><creator>Yadav, Madhav P</creator><creator>Bal, Chandrasekhar</creator><creator>Jeong, Chang Wook</creator><creator>Kwak, Cheol</creator><creator>Cheon, Gi Jeong</creator><general>Society of Nuclear Medicine</general><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20211001</creationdate><title>Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study</title><author>Suh, Minseok ; Im, Hyung-Jun ; Ryoo, Hyun Gee ; Kang, Keon Wook ; Jeong, Jae Min ; Prakash, Sneha ; Ballal, Sanjana ; Yadav, Madhav P ; Bal, Chandrasekhar ; Jeong, Chang Wook ; Kwak, Cheol ; Cheon, Gi Jeong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1594-4e949d059ec473c0d79f0b7c9fbc88451d7c4b47ca05d46dab4ee6dc52216c5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Brief Communications</topic><topic>Computed tomography</topic><topic>Lesions</topic><topic>Medical imaging</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Organs</topic><topic>Positron emission</topic><topic>Prostate cancer</topic><topic>Tomography</topic><topic>Urea</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suh, Minseok</creatorcontrib><creatorcontrib>Im, Hyung-Jun</creatorcontrib><creatorcontrib>Ryoo, Hyun Gee</creatorcontrib><creatorcontrib>Kang, Keon Wook</creatorcontrib><creatorcontrib>Jeong, Jae Min</creatorcontrib><creatorcontrib>Prakash, Sneha</creatorcontrib><creatorcontrib>Ballal, Sanjana</creatorcontrib><creatorcontrib>Yadav, Madhav P</creatorcontrib><creatorcontrib>Bal, Chandrasekhar</creatorcontrib><creatorcontrib>Jeong, Chang Wook</creatorcontrib><creatorcontrib>Kwak, Cheol</creatorcontrib><creatorcontrib>Cheon, Gi Jeong</creatorcontrib><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suh, Minseok</au><au>Im, Hyung-Jun</au><au>Ryoo, Hyun Gee</au><au>Kang, Keon Wook</au><au>Jeong, Jae Min</au><au>Prakash, Sneha</au><au>Ballal, Sanjana</au><au>Yadav, Madhav P</au><au>Bal, Chandrasekhar</au><au>Jeong, Chang Wook</au><au>Kwak, Cheol</au><au>Cheon, Gi Jeong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2021-10-01</date><risdate>2021</risdate><volume>62</volume><issue>10</issue><spage>1457</spage><epage>1460</epage><pages>1457-1460</pages><issn>0161-5505</issn><issn>1535-5667</issn><eissn>1535-5667</eissn><abstract>68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.</abstract><cop>New York</cop><pub>Society of Nuclear Medicine</pub><pmid>33637585</pmid><doi>10.2967/jnumed.120.258434</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | The Journal of nuclear medicine (1978), 2021-10, Vol.62 (10), p.1457-1460 |
| issn | 0161-5505 1535-5667 1535-5667 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8724887 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antigens Brief Communications Computed tomography Lesions Medical imaging Metastases Metastasis Organs Positron emission Prostate cancer Tomography Urea |
| title | Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A32%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Head-to-Head%20Comparison%20of%2068Ga-NOTA%20(68Ga-NGUL)%20and%2068Ga-PSMA-11%20in%20Patients%20with%20Metastatic%20Prostate%20Cancer:%20A%20Prospective%20Study&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Suh,%20Minseok&rft.date=2021-10-01&rft.volume=62&rft.issue=10&rft.spage=1457&rft.epage=1460&rft.pages=1457-1460&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.120.258434&rft_dat=%3Cproquest_pubme%3E2580728766%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2580728766&rft_id=info:pmid/33637585&rfr_iscdi=true |